← Leaderboards
Casey Long
Dynport Vaccine Company, Llc
$2,265,501
Attributed
$2,265,501
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.8M · FY2023–24$2M$1.5M$1M$500K$0
'23
'24
Funding mix
By agency
NIH$2,265,501 · 1
By mechanism
N01$2,265,501 · 1
Top collaborators
No co-investigators on record.
Most similar at Dynport Vaccine Company, Llc
Same institution · by research overlap
- Graig Shockey$9,887,057
- Salama Balume$16,877,312
- David Shumway$6,214,596
- George Saviolakis$1,316,543
- Preston Holley$300,000
Others in their field
Other Rising Stars on “Clinical Trial Implementation”
- Thierry Diagana · University Of Texas Med Br Galveston$37,506,320
- Thomas K Karikari · Wake Forest University Health Sciences$14,340,584
- Jennifer Lee O'Brien · University Of South Florida$10,506,386
- Songthip T. Ounpraseuth · Univ Of Arkansas For Med Scis$10,363,762
- Cathryn Peltz · Henry Ford Health + Michigan State University Health Sciences$7,977,678
- Yan Ji · Healthpartners Institute$5,300,768
Research focus
Clinical Trial ImplementationClinical Trials UnitCommunicable DiseasesCovid-19 TherapeuticsEarly Phase Clinical TrialInvestigationNew AgentsPhase I Clinical TrialsPreventionPlacebo ControlClinical TrialsNational Institute Of Allergy And Infectious DiseaseStudy SubjectRandomizedPhase 1 StudyDoseDouble-Blind MethodCoronavirus Disease
Grant awards (3)
Task C1: A Randomized, Double Blind, Placebo-Controlled, Multiple Ascending Dose Phase 1 Study of SARS-CoV-2 Therapeutics$245,549
N01 · FY2024 · AI · contact PI
Task C1: A Randomized, Double Blind, Placebo-Controlled, Multiple Ascending Dose Phase 1 Study of SARS-CoV-2 Therapeutics$219,169
N01 · FY2024 · AI · contact PI
EARLY PHASE CLINICAL TRIAL UNITS (EPCTU): PHASE I CLINICAL TRIAL TO EVALUATE A SARS-COV-2 THERAPEUTIC$1,800,783
N01 · FY2023 · AI · contact PI